Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthélabo, dated April 25, 2003, reports on recent events and provides a comprehensive summary of the company's 2002 financial performance and strategic outlook. The reporting period covers the fiscal year ended December 31, 2002, with updates on clinical trials and regulatory approvals extending into early 2003. The company, a major global pharmaceutical group, celebrated its 30th anniversary in 2003 and continued its expansion in the United States following its July 2002 listing on the New York Stock Exchange.
Key Financial Metrics (2002)
| Metric | Value (Millions of Euros) | Change vs. 2001 |
|---|---|---|
| Consolidated Net Sales | 7,448 | +14.8% (Reported) / +12.8% (Comparable) |
| Operating Profit | 2,614 | +24.1% |
| Operating Margin | 35.1% | +2.6 percentage points |
| Net Income | 1,759 | +11.0% |
| Net Income (Excl. Exceptional Items/Goodwill) | 1,758 | +27.8% |
| Earnings Per Share (Excl. Exceptional Items/Goodwill) | 2.42 Euros | +28.7% |
| Research & Development Expenses | 1,218 | +18.1% |
| Operating Cash Flow (Before Working Capital) | 2,260 | +30.5% |
| Net Cash Position (Year End) | 2,672 | -31.2% (vs. 3,885 in 2001) |
Debt and Liquidity: The company maintained a strong liquidity position with a net cash balance of 2,672 million euros as of December 31, 2002. Total financial debt (short and long-term) was 416 million euros. The decline in net cash was primarily due to significant share repurchases (963 million euros) and capital expenditures (1,435 million euros), including the acquisition of Pharmacia's interest in the Lorex joint venture.
Material Changes vs. Prior Period
- Revenue Growth Drivers: Sales growth was driven by the three flagship products (Plavix, Aprovel, Stilnox/Ambien), which generated 2,973 million euros in consolidated sales (+32.1% comparable). The U.S. market contributed significantly, with consolidated sales rising 17.5% and developed sales rising 32%.
- Acquisitions and Consolidation: The company acquired the remaining 51% interest in Lorex Pharmaceuticals (marketer of Ambien in the U.S.) from Pharmacia in April 2002, resulting in 100% consolidation of Ambien sales starting January 1, 2002. This significantly boosted reported sales growth.
- Product Launches: Key 2002 launches included Eloxatin (colorectal cancer) in the U.S., Arixtra (thrombosis prophylaxis) in the U.S. and Europe, and Eligard (prostate cancer) in the U.S.
- Challenges: The company faced headwinds from foreign exchange fluctuations (costing 2.5 percentage points of sales growth) and a stock-reduction program by partner Bristol-Myers Squibb for Plavix and Avapro in the U.S., which temporarily limited sales despite increased prescriptions.
Guidance, Outlook, and Risks
2003 Outlook: Management expects continued double-digit sales growth and an increase in consolidated earnings per share of approximately 20% (before exceptional items and goodwill amortization), assuming a 1:1 Euro-to-Dollar exchange rate. Growth is expected to be driven by flagship products, the expansion of Eloxatin sales in the U.S., and the performance of the broader portfolio (Depakine, Solian, Xatral).
Management Commentary: The Chairman emphasized that despite an unfavorable economic environment, the company met its objectives. The R&D pipeline remains robust with 52 compounds in development, including 23 in advanced phases. The company is confident in its ability to sustain growth through innovation and life-cycle management of existing products.
Risks and Contingencies:
- Clinical Trial Interruption: The ANDROMEDA study for dronedarone (atrial fibrillation) was stopped in January 2003 due to tolerability concerns in high-risk heart failure patients. However, efficacy studies (EURIDIS and ADONIS) continue.
- Patent Litigation: Two generic manufacturers (Apotex and Dr. Reddy's Laboratories) challenged Plavix patents in the U.S. Sanofi-Synthélabo is vigorously defending these patents, which are critical to its business.
- Regulatory and Pricing Pressure: The company faces ongoing pressure from healthcare cost-containment measures in Europe and the U.S., as well as the risk of generic competition for products losing patent protection (e.g., Primacor).
Key Facts for Investor Verification
- Plavix Patent Defense: Verify the status of the ongoing litigation against Apotex and Dr. Reddy's Laboratories regarding Plavix patents, as a loss could significantly impact future revenue.
- Dronedarone Development: Monitor the outcome of the analysis of the ANDROMEDA study data and the potential for a new protocol, as this compound is a key successor to Cordarone.
- U.S. Market Execution: Confirm the continued growth trajectory of U.S. sales, particularly for Eloxatin and Ambien, given the company's strategic focus on this market.
- Share Repurchase Program: Track the progress of the share repurchase program, which increased treasury shares to 5.26% of capital by February 2003, and its impact on earnings per share.
- Exchange Rate Sensitivity: Assess the impact of Euro/Dollar fluctuations on 2003 results, as management's guidance assumes parity.